645 related articles for article (PubMed ID: 23511665)
1. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
2. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
3. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
4. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
5. Overcoming castration resistance in prostate cancer.
Tsao CK; Small AC; Galsky MD; Oh WK
Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
[TBL] [Abstract][Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
8. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
9. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
10. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
12. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Sartor AO
J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
[TBL] [Abstract][Full Text] [Related]
13. Targeting continued androgen receptor signaling in prostate cancer.
Massard C; Fizazi K
Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
[TBL] [Abstract][Full Text] [Related]
14. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
15. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Bryce A; Ryan CJ
Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
17. Secondary hormonal therapy.
Smith DC
Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
[TBL] [Abstract][Full Text] [Related]
18. Novel hormonal therapy for castration-resistant prostate cancer.
Sternberg CN
Ann Oncol; 2012 Sep; 23 Suppl 10():x259-63. PubMed ID: 22987973
[No Abstract] [Full Text] [Related]
19. Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M; Winquist E
Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
[TBL] [Abstract][Full Text] [Related]
20. Progress in emerging therapies for advanced prostate cancer.
Oudard S
Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
